Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Monthly injectable naltrexone for pathological gambling.

Yoon G, Kim SW.

Am J Psychiatry. 2013 Jun;170(6):682-3. doi: 10.1176/appi.ajp.2013.12111469. No abstract available.

PMID:
23732971
2.

Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease.

Bosco D, Plastino M, Colica C, Bosco F, Arianna S, Vecchio A, Galati F, Cristiano D, Consoli A, Consoli D.

Clin Neuropharmacol. 2012 May-Jun;35(3):118-20. doi: 10.1097/WNF.0b013e31824d529b.

PMID:
22426027
3.

Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study.

Grant JE, Odlaug BL, Potenza MN, Hollander E, Kim SW.

Br J Psychiatry. 2010 Oct;197(4):330-1. doi: 10.1192/bjp.bp.110.078105. Erratum in: Br J Psychiatry. 2011 Jan;198:75.

4.
6.

Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study.

Dannon PN, Lowengrub K, Musin E, Gonopolski Y, Kotler M.

J Clin Psychopharmacol. 2005 Dec;25(6):593-6.

PMID:
16282845
7.

Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.

Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL.

Addiction. 2013 Sep;108(9):1628-37. doi: 10.1111/add.12208. Epub 2013 May 24.

PMID:
23701526
8.

Long-acting depot formulations of naltrexone for heroin dependence: a review.

Krupitsky EM, Blokhina EA.

Curr Opin Psychiatry. 2010 May;23(3):210-4. doi: 10.1097/YCO.0b013e3283386578. Review.

PMID:
20224403
9.

An open naltrexone treatment study in pathological gambling disorder.

Kim SW, Grant JE.

Int Clin Psychopharmacol. 2001 Sep;16(5):285-9.

PMID:
11552772
10.

Meta-analysis: pharmacological treatment of pathological gambling.

Bartley CA, Bloch MH.

Expert Rev Neurother. 2013 Aug;13(8):887-94. doi: 10.1586/14737175.2013.814938. Epub 2013 Aug 16.

PMID:
23952195
11.

Pathological gambling. Current status and new treatments.

Kim SW, Grant JE, Grosz RL.

Minn Med. 2002 Jul;85(7):48-50, 52.

PMID:
12152529
12.
13.

Naltrexone (vivitrol)--a once-monthly injection for alcoholism.

[No authors listed]

Med Lett Drugs Ther. 2006 Jul 31;48(1240):63-4. No abstract available.

PMID:
16874283
14.

Four-year follow-up study of pharmacological treatment in pathological gamblers.

Rosenberg O, Dinur LK, Dannon PN.

Clin Neuropharmacol. 2013 Mar-Apr;36(2):42-5. doi: 10.1097/WNF.0b013e31828740ea.

PMID:
23503545
15.

12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study.

Dannon PN, Lowengrub K, Musin E, Gonopolsky Y, Kotler M.

J Clin Psychopharmacol. 2007 Dec;27(6):620-4.

PMID:
18004130
16.

Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.

Lucey MR, Silverman BL, Illeperuma A, O'Brien CP.

Alcohol Clin Exp Res. 2008 Mar;32(3):498-504. doi: 10.1111/j.1530-0277.2007.00593.x. Epub 2008 Jan 30.

PMID:
18241321
17.

Long-acting injectable naltrexone for the treatment of alcohol dependence.

Mannelli P, Peindl K, Masand PS, Patkar AA.

Expert Rev Neurother. 2007 Oct;7(10):1265-77. Review.

PMID:
17939765
18.

Naltrexone in the treatment of pathological gambling and alcohol dependence.

Crockford DN, el-Guebaly N.

Can J Psychiatry. 1998 Feb;43(1):86. No abstract available.

PMID:
9494755
19.

Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling.

Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, Kallio A.

Am J Psychiatry. 2006 Feb;163(2):303-12.

PMID:
16449486
20.

Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling.

Kim SW, Grant JE, Adson DE, Shin YC.

Biol Psychiatry. 2001 Jun 1;49(11):914-21.

PMID:
11377409

Supplemental Content

Support Center